SEC Company Response from Protara Therapeutics, Inc. (TARA) (CIK 0001359931) (TARA) — Oct 17, 2014
Protara Therapeutics, Inc. (TARA) (CIK 0001359931)
Date: Oct. 17, 2014 · CIK: 0001359931 · Accession: 0001104659-14-072225
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-198777
Letter
Proteon Therapeutics, Inc. 200 West Street
(781) 890-0102
October 17, 2014
Via EDGAR and Facsimile
United States Securities and Exchange Commission
Division of Corporate Finance
100 F Street, NE
Washington, D.C. 20549
Attn: John Krug and Christina De Rosa
RE: Proteon Therapeutics, Inc.
Registration Statement on Form S-1
SEC File No. 333-198777
Ladies and Gentlemen:
Pursuant to Rule 461 of the Securities Act of 1933, as amended, Proteon Therapeutics, Inc., a Delaware corporation (the “Company”), hereby requests that the effectiveness of the Company’s above-referenced Registration Statement on Form S-1, as amended (the “Registration Statement”), be accelerated to 4:00 p.m. Eastern Time, on October 21, 2014 or as soon as practicable thereafter, unless you are orally or in writing notified to the contrary by the Company prior to such date and time. In the event you are orally notified, you will be contacted either by William S. Perkins or Julio E. Vega of Bingham McCutchen LLP, or myself.
The Company hereby acknowledges that:
· should the Securities and Exchange Commission (the “Commission”) or the staff of the Commission (the “Staff”), acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
· the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
· the Company may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Should you have any questions regarding this request, please do not hesitate to contact William S. Perkins at (617) 951-8574 of Bingham McCutchen LLP, counsel to the Company.
Please contact William S. Perkins as soon as the Registration Statement has been declared effective.
Sincerely,
PROTEON THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm Proteon Therapeutics, Inc. 200 West Street (781) 890-0102 October 17, 2014 Via EDGAR and Facsimile United States Securities and Exchange Commission Division of Corporate Finance 100 F Street, NE Washington, D.C. 20549 Attn: John Krug and Christina De Rosa RE: Proteon Therapeutics, Inc. Registration Statement on Form S-1 SEC File No. 333-198777 Ladies and Gentlemen: Pursuant to Rule 461 of the Securities Act of 1933, as amended, Proteon Therapeutics, Inc., a Delaware corporation (the “Company”), hereby requests that the effectiveness of the Company’s above-referenced Registration Statement on Form S-1, as amended (the “Registration Statement”), be accelerated to 4:00 p.m. Eastern Time, on October 21, 2014 or as soon as practicable thereafter, unless you are orally or in writing notified to the contrary by the Company prior to such date and time. In the event you are orally notified, you will be contacted either by William S. Perkins or Julio E. Vega of Bingham McCutchen LLP, or myself. The Company hereby acknowledges that: · should the Securities and Exchange Commission (the “Commission”) or the staff of the Commission (the “Staff”), acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; · the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and · the Company may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Should you have any questions regarding this request, please do not hesitate to contact William S. Perkins at (617) 951-8574 of Bingham McCutchen LLP, counsel to the Company. Please contact William S. Perkins as soon as the Registration Statement has been declared effective. Sincerely, PROTEON THERAPEUTICS, INC. /s/ George A. Eldridge Name: George A. Eldridge Title: Senior Vice President, Chief Financial Officer, Treasurer and Secretary cc: Timothy Noyes, Proteon Therapeutics, Inc. Julio E. Vega, Bingham McCutchen LLP William S. Perkins, Bingham McCutchen LLP Patrick O’Brien, Ropes & Gray LLP